D. E. Shaw & Co., Inc. Ultragenyx Pharmaceutical Inc. Call Options Transaction History
D. E. Shaw & Co., Inc.
- $107 Billion
- Q3 2024
Call Options
1 transactions
Others Institutions Holding RARE
# of Institutions
325Shares Held
85.6MCall Options Held
520KPut Options Held
406K-
Vanguard Group Inc Valley Forge, PA9.95MShares$420 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.6MShares$237 Million0.01% of portfolio
-
Sands Capital Management, LLC Arlington, VA5.12MShares$216 Million0.91% of portfolio
-
Wellington Management Group LLP Boston, MA4.17MShares$176 Million0.04% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.07MShares$130 Million0.02% of portfolio
About Ultragenyx Pharmaceutical Inc.
- Ticker RARE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,036,896
- Market Cap $2.96B
- Description
- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...